Levi & Korsinsky Launches Class Action Against Merck for Investor Recovery Amid Securities Fraud Claims
Class Action Filed Against Merck & Co., Inc.
In a significant legal move, Levi & Korsinsky, LLP has officially filed a class action lawsuit against Merck & Co., Inc. (commonly referred to as Merck) on behalf of investors who experienced losses related to alleged securities fraud. This lawsuit is particularly aimed at those who held shares between February 3, 2022, and February 3, 2025.
Background of the Allegations
The legal complaint asserts that key figures at Merck provided misleading information about the company's future revenue, projected to be $11 billion from vaccine sales of Gardasil by 2030. The firm touted its expected capability to catalyze demand through successful marketing and educational efforts regarding Gardasil’s advantages. Investors were led to believe that such promotional activities would result in significant growth in the Chinese market for this vaccine.
However, the reality hit on February 4, 2025, when Merck disclosed that it would not achieve the previously anticipated sales figures for Gardasil by 2030. The company ceased shipments of the vaccine to China, citing a need to reduce excess inventory due to lackluster demand, which had not rebounded to expected levels. This announcement triggered a dramatic decline in Merck’s stock price, which dropped from a closing rate of $99.79 per share on February 3, 2025, to $90.74 the following day—a steeper than 9% plunge in just 24 hours.
The Legal Implications
As part of the class action proceedings, interested parties who suffered financial losses during the specified period have until April 14, 2025, to seek designation as lead plaintiff. Merck investors are not obliged to be lead plaintiffs to participate in any potential recovery and are encouraged to get in touch with legal representatives to understand their rights and options.
Levi & Korsinsky has reiterated that there will be no cost for class members to join the lawsuit, ensuring that participation does not incur out-of-pocket expenses for investors. This class action represents an opportunity for those affected by Merck's actions to seek redress without financial barriers.
Why Choose Levi & Korsinsky?
Levi & Korsinsky has a robust history in securities law, successfully securing hundreds of millions of dollars for shareholders over the past two decades. Their reputation is further bolstered by their consistent recognition as one of the top firms in the field of securities litigation, as cited in the ISS Securities Class Action Services' Top 50 Report for seven consecutive years. Their team is comprised of over 70 skilled professionals with extensive experience in complex securities lawsuits.
In conclusion, as this lawsuit unfolds, the focus will remain on the validity of Merck's prior claims about Gardasil and the ramifications of the altered financial expectations. Investors are urged to stay aware of their rights under the ongoing legal framework established by this significant class action initiative. For more details or to explore joining the lawsuit, interested investors may contact Joseph E. Levi, Esq. at (212) 363-7500 or email at JLevi@zlk.com.
Contact Information
- - Levi & Korsinsky, LLP
New York, NY 10004
Phone: (212) 363-7500
Fax: (212) 363-7171
Website: www.zlk.com
This case serves as a vital reminder of the importance of transparency in corporate communication and investors' rights to accurate financial disclosures.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.